Comparison of Treatment Effect Estimates for Pharmacological Randomized Controlled Trials Enrolling Older Adults Only and Those including Adults: A Meta-Epidemiological Study

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Seegers, Valérie ^a,b   Trinquart, Ludovic ^a,b,c,d   Boutron, Isabelle ^a,b,c,d   Ravaud, Philippe ^a,b,c,d,e  

^a HÔTEL DIEU   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d French Cochrane Centre   (France)

^e Columbia University Mailman School of Public Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGE DISTRIBUTION; AGED; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL ASSESSMENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; ELDERLY CARE; EPIDEMIOLOGICAL MONITORING; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MENTAL DISEASE; META ANALYSIS (TOPIC); NEUROLOGIC DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; EPIDEMIOLOGIC STUDIES; GENETIC HETEROGENEITY; HUMANS; ODDS RATIO; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84878417925     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063677     Document Type: Review

References (57)

1. WHO website. Available: http://www.who.int/features/factfiles/ageing/en/index.html. Accessed: 2012 May 15.
2. Scott IA, Guyatt GH, (2010) Cautionary tales in the interpretation of clinical studies involving older persons. Arch Intern Med 170: 587-595.
3. Cherubini A, Oristrell J, Pla X, Ruggiero C, Ferretti R, et al. (2011) The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med 171: 550-556.
4. Gurwitz JH, Col NF, Avorn J, (1992) The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA 268: 1417-1422.
5. Gurwitz JH, Goldberg RJ, (2011) Age-based exclusions from cardiovascular clinical trials: implications for elderly individuals (and for all of us): comment on "the persistent exclusion of older patients from ongoing clinical trials regarding heart failure". Arch Intern Med 171: 557-558.
6. Heiat A, Gross CP, Krumholz HM, (2002) Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 162: 1682-1688.
7. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS, (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341: 2061-2067.
8. Konrat C, Boutron I, Trinquart L, Auleley GR, Ricordeau P, et al. (2012) Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS One 7: e33559.
9. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, et al. (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21: 1383-1389.
10. Scott IA (2010) Cautionary Tales in the Interpretation of Clinical Studies Involving Older Persons. Arch Intern Med 170 587-595.
11. McMurdo ME, Roberts H, Parker S, Wyatt N, May H, et al. (2011) Improving recruitment of older people to research through good practice. Age Ageing 40: 659-665.
12. McMurdo ME, Witham MD, Gillespie ND, (2005) Including older people in clinical research. BMJ 331: 1036-1037.
13. Murray MD, Callahan CM, (2003) Improving medication use for older adults: an integrated research agenda. Ann Intern Med 139: 425-429.
14. Van Spall HG, Toren A, Kiss A, Fowler RA, (2007) Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 297: 1233-1240.
15. PREDICT (2008) Increasing the participation of the elderly in clinical trials.
16. European Forum for Good Clinical Practice Geriatric research guidelines.
17. Pallis AG, Ring A, Fortpied C, Penninckx B, Van Nes MC, et al. (2011) EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. Ann Oncol 22: 1922-1926.
18. Sinha G, (2006) Geriatric oncology aims for clinical trials. J Natl Cancer Inst 98: 1516-1518.
19. Watts G, (2012) Why the exclusion of older people from clinical research must stop. BMJ 344: e3445.
20. Herrera AP, Snipes SA, King DW, Torres-Vigil I, Goldberg DS, et al. (2010) Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health 100Suppl 1: S105-112.
21. Ridda I, Lindley R, MacIntyre RC, (2008) The challenges of clinical trials in the exclusion zone: the case of the frail elderly. Australas J Ageing 27: 61-66.
22. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717.
23. Bozkurt B, Agoston I, Knowlton AA, (2003) Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 41: 211-214.
24. Sterne JA, Juni P, Schulz KF, Altman DG, Bartlett C, et al. (2002) Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research. Stat Med 21: 1513-1524.
25. Naylor CD, (1997) Meta-analysis and the meta-epidemiology of clinical research. BMJ 315: 617-619.
26. Schulz KF, Chalmers I, Hayes RJ, Altman DG, (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273: 408-412.
27. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, et al. (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352: 609-613.
28. Pildal J, Hrobjartsson A, Jorgensen KJ, Hilden J, Altman DG, et al. (2007) Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol 36: 847-857.
29. Nuesch E, Reichenbach S, Trelle S, Rutjes AW, Liewald K, et al. (2009) The importance of allocation concealment and patient blinding in osteoarthritis trials: a meta-epidemiologic study. Arthritis Rheum 61: 1633-1641.
30. Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P, (2011) Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study. Ann Intern Med 155: 39-51.
31. Bafeta A, Dechartres A, Trinquart L, Yavchitz A, Boutron I, et al. (2012) Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study. BMJ 344: e813.
32. Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, et al. (2001) Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 286: 821-830.
33. Contopoulos-Ioannidis DG, Baltogianni MS, Ioannidis JP (2010) Comparative effectiveness of medical interventions in adults versus children. J Pediatr 157: 322-330 e317.
34. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, et al. (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343: d5928.
35. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
36. Sweeting MJ, Sutton AJ, Lambert PC, (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23: 1351-1375.
37. Altman DG, Bland JM, (2003) Interaction revisited: the difference between two estimates. BMJ 326: 219.
38. Golder S, Loke YK, Bland M, (2011) Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 8: e1001026.
39. Riley RD, Higgins JP, Deeks JJ, (2011) Interpretation of random effects meta-analyses. BMJ 342: d549.
40. Baujat B, Mahe C, Pignon JP, Hill C, (2002) A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med 21: 2641-2652.
41. Siersma V, Als-Nielsen B, Chen W, Hilden J, Gluud LL, et al. (2007) Multivariable modelling for meta-epidemiological assessment of the association between trial quality and treatment effects estimated in randomized clinical trials. Stat Med 26: 2745-2758.
42. R Development Core Team (2012) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing,.
43. Guido Schwarzer (2012) meta: Meta-Analysis with R. R package version 2.1-0.
44. Wolfgang Viechtbauer, (2010) Conducting meta-analyses in R with the metafor package. Journal of Statistical Software 36: 1-48.
45. Bates D, Maechler M, Bolker B (2012) lme4: Linear mixed-effects models using S4 classes. 0.999999-0 ed.
46. Simon SR, Gurwitz JH, (2003) Drug therapy in the elderly: improving quality and access. Clin Pharmacol Ther 73: 387-393.
47. Gurwitz JH, Rochon P, (2002) Improving the quality of medication use in elderly patients: a not-so-simple prescription. Arch Intern Med 162: 1670-1672.
48. Jencks SF, Cuerdon T, Burwen DR, Fleming B, Houck PM, et al. (2000) Quality of medical care delivered to Medicare beneficiaries: A profile at state and national levels. JAMA 284: 1670-1676.
49. Higashi T, Shekelle PG, Solomon DH, Knight EL, Roth C, et al. (2004) The quality of pharmacologic care for vulnerable older patients. Ann Intern Med 140: 714-720.
50. Pitrou I, Boutron I, Ahmad N, Ravaud P, (2009) Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 169: 1756-1761.
51. Papanikolaou PN, Christidi GD, Ioannidis JP, (2006) Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 174: 635-641.
52. Ioannidis JP, Lau J, (2001) Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 285: 437-443.
53. Cuervo LG, Clarke M, (2003) Balancing benefits and harms in health care. BMJ 327: 65-66.
54. The Association of Anaesthetists of Great Britain and Ireland (2001) Anaesthesia and Peri-Operative Care of the Elderly. London.
55. Olsen O, Middleton P, Ezzo J, Gotzsche PC, Hadhazy V, et al. (2001) Quality of Cochrane reviews: assessment of sample from 1998. BMJ 323: 829-832.
56. Juni P, Witschi A, Bloch R, Egger M, (1999) The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282: 1054-1060.
57. Ioannidis JP, Lau J, (1998) Can quality of clinical trials and meta-analyses be quantified? Lancet 352: 590-591.